A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study was conducted to explore the effect of adding active vitamin D to nutritional vitamin D supplement on proteinuria and kidney function in CKD with vitamin D insufficiency/deficiency.

(Thai Clinical Trials Registry (TCTR) 20140929002 ).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

This double-blind, randomized placebo-controlled trial was performed to answer the above question.

What Was Measured

The subject headings attached to it are Blood Pressure, Calcitriol, Creatinine, Ergocalciferols, Glomerular Filtration Rate, Proteinuria and Renal Insufficiency, Chronic.

Author keywords: CKD and Vitamin D deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (BMC nephrology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.